HOUSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces...
In a paper published in today’s online issue of the Journal of Alzheimer’s Disease (DOI 10.3233/JAD-190772), TauRx has reported unexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological...
IMVT-1401, a fully human anti-FcRn antibody designed to be administered via subcutaneous injection, is the only anti-FcRn antibody known to be in clinical development for the treatment of GO Topline results from the ASCEND-GO 2 program are expected in early 2021...
GENFIT: Positive 42-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH Data Safety Monitoring Board (DSMB) recommends the continuation of the RESOLVE-IT clinical trial without any modifications, based on the pre-planned...
With the advent of digital media, the ability to reach a wide audience has never been easier. A patient recruitment company isn’t limited to traditional methods, as digital platforms can be a vital tool when implemented to reach patients for future trials....
Email
Text